J&J sees itself as 'important player' in hepatitis C competition
This article was originally published in Scrip
Executive Summary
Compared with some of its rivals, Johnson & Johnson seems downright stealth about its approach to developing new treatments for hepatitis C, the liver-destroying virus that is believed to infect tens of millions of people around the world.
You may also be interested in...
Baxter's Advate helps prevent bleeding in one-year study of hemophiliacs
Using Baxter’s Advate drug as a preventative therapy helped significantly reduce bleeding incidents in a yearlong study.
Mylan CEO Bresch is looking to do a sizable deal
Mylan CEO Heather Bresch said she is looking to do a sizable deal that helps the US generic and specialty drug maker better compete in a consolidating field of rivals.
Biogen's Scangos sees potential to dominate hemophilia market
Biogen Idec CEO George Scangos is frank about his ambitions to dominate the market for hemophilia therapies, an opportunity he compares to the big biotech’s lead treating multiple sclerosis.